Pharma

Your Article Summary

See Latest Articles

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Boston Scientific, 02/06/09

Boston Scientific Corporation announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final modules of the Company's Pre-Market Approval (PMA) applications for both its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System and its TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System. If approved, the TAXUS Liberte Atom Stent will become the Company's second 2.25 mm diameter drug-eluting stent available in the United States. It will then likely succeed the TAXUS Express Atom Stent, which is the Company's first approved small stent and the only DES currently approved by the FDA to treat small vessels. The TAXUS Liberte Long Stent is designed to be the first 38 mm drug-eluting stent available in the U.S. and will further expand the Company's leading DES portfolio.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals